$23.86 Million in Sales Expected for Juno Therapeutics Inc (JUNO) This Quarter

Wall Street analysts predict that Juno Therapeutics Inc (NASDAQ:JUNO) will post sales of $23.86 million for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Juno Therapeutics’ earnings. The highest sales estimate is $44.80 million and the lowest is $17.00 million. Juno Therapeutics posted sales of $21.15 million in the same quarter last year, which suggests a positive year-over-year growth rate of 12.8%. The business is scheduled to report its next quarterly earnings results on Wednesday, March 7th.

According to Zacks, analysts expect that Juno Therapeutics will report full year sales of $23.86 million for the current financial year, with estimates ranging from $85.00 million to $130.20 million. For the next fiscal year, analysts forecast that the company will post sales of $77.82 million per share, with estimates ranging from $50.00 million to $135.50 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Juno Therapeutics.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.07. The business had revenue of $44.80 million during the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business’s revenue was up 115.4% on a year-over-year basis. During the same period last year, the business earned ($0.57) EPS.

A number of equities research analysts recently weighed in on the stock. Morgan Stanley reaffirmed an “equal weight” rating and set a $43.00 price target (up from $27.00) on shares of Juno Therapeutics in a report on Friday, October 6th. Maxim Group reaffirmed a “buy” rating and set a $56.00 price target on shares of Juno Therapeutics in a report on Thursday, November 2nd. Leerink Swann reaffirmed an “in-line” rating and set a $56.00 price target (up from $34.00) on shares of Juno Therapeutics in a report on Thursday, November 2nd. Cowen reaffirmed a “buy” rating on shares of Juno Therapeutics in a report on Friday, November 3rd. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and set a $44.00 price target on shares of Juno Therapeutics in a report on Friday, October 6th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $45.48.

In other Juno Therapeutics news, CFO Steve Harr sold 8,750 shares of the stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $44.76, for a total transaction of $391,650.00. Following the transaction, the chief financial officer now directly owns 772,082 shares in the company, valued at approximately $34,558,390.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Robert Azelby sold 1,816 shares of the stock in a transaction on Monday, December 18th. The shares were sold at an average price of $44.96, for a total transaction of $81,647.36. Following the transaction, the executive vice president now owns 70,832 shares in the company, valued at $3,184,606.72. The disclosure for this sale can be found here. Insiders have sold a total of 53,232 shares of company stock worth $2,450,954 over the last quarter. 15.08% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of JUNO. The Manufacturers Life Insurance Company lifted its position in shares of Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares during the last quarter. Pacad Investment Ltd. bought a new position in shares of Juno Therapeutics in the 2nd quarter worth about $105,000. Advisor Group Inc. lifted its position in shares of Juno Therapeutics by 141.1% in the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,439 shares during the last quarter. QS Investors LLC bought a new position in shares of Juno Therapeutics in the 2nd quarter worth about $135,000. Finally, Bronfman E.L. Rothschild L.P. lifted its position in shares of Juno Therapeutics by 27,376.9% in the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 3,559 shares during the last quarter. Hedge funds and other institutional investors own 69.94% of the company’s stock.

Juno Therapeutics (JUNO) traded up $0.74 on Wednesday, reaching $48.09. 1,240,000 shares of the company were exchanged, compared to its average volume of 2,280,000. The firm has a market cap of $5,490.00, a price-to-earnings ratio of -14.19 and a beta of 2.32. Juno Therapeutics has a 1-year low of $18.90 and a 1-year high of $63.45. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.77 and a current ratio of 4.77.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/03/23-86-million-in-sales-expected-for-juno-therapeutics-inc-juno-this-quarter-2.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Get a free copy of the Zacks research report on Juno Therapeutics (JUNO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply